ICT
MCID: CRC014
MIFTS: 50

Carcinoid Tumors, Intestinal (ICT)

Categories: Genetic diseases, Endocrine diseases, Rare diseases, Gastrointestinal diseases, Cancer diseases

Aliases & Classifications for Carcinoid Tumors, Intestinal

MalaCards integrated aliases for Carcinoid Tumors, Intestinal:

Name: Carcinoid Tumors, Intestinal 57 13
Gastrointestinal Carcinoid Tumor 75 55 73
Carcinoid 75 37 55
Malignant Carcinoid Syndrome 59 73
Carcinoid Tumor 44 73
Argentaffinoma 75 73
Carcinoid Tumor No Icd-O Subtype 73
Tumor, Carcinoid, Intestinal 40
Carcinoid Tumor of Intestine 73
Intestinal Carcinoid Tumor 75
Carcinoid Syndrome 59
Ict 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
carcinoid tumors, intestinal:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare endocrine diseases


External Ids:

OMIM 57 114900
Orphanet 59 ORPHA100093
ICD10 via Orphanet 34 E34.0
MedGen 42 C0349535
MeSH 44 D002276
KEGG 37 H00034
SNOMED-CT via HPO 69 263681008

Summaries for Carcinoid Tumors, Intestinal

UniProtKB/Swiss-Prot : 75 Intestinal carcinoid tumor: A yellow, well-differentiated, circumscribed tumor that arises from enterochromaffin cells in the small intestine or, less frequently, in other parts of the gastrointestinal tract.

MalaCards based summary : Carcinoid Tumors, Intestinal, also known as gastrointestinal carcinoid tumor, is related to carcinoid syndrome and serotonin syndrome. An important gene associated with Carcinoid Tumors, Intestinal is SDHD (Succinate Dehydrogenase Complex Subunit D), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Neuroscience. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include small intestine, liver and breast, and related phenotypes are intestinal carcinoid and carcinoid tumor

Description from OMIM: 114900

Related Diseases for Carcinoid Tumors, Intestinal

Diseases related to Carcinoid Tumors, Intestinal via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 carcinoid syndrome 32.1 CHGA ENO2 MEN1 SST SYP
2 serotonin syndrome 30.4 CHGA MEN1 NOTCH1 SST
3 vipoma 30.0 CHGA SST
4 somatostatinoma 29.6 CHGA ENO2 SST
5 zollinger-ellison syndrome 29.4 CHGA MEN1 SST
6 adenoma 29.4 MEN1 SST SSTR2
7 gastrointestinal neuroendocrine tumor 29.3 CHGA SST SYP
8 acromegaly 29.0 MEN1 SST SSTR2
9 multiple endocrine neoplasia, type i 27.7 CHGA MEN1 SDHD SST SYP
10 pheochromocytoma 25.9 CHGA CHGB ENO2 MEN1 SDHD SST
11 neuroendocrine tumor 24.9 CHGA CHGB ENO2 MEN1 NKX2-1 SDHD
12 neurofibromatosis-pheochromocytoma-duodenal carcinoid syndrome 12.0
13 connective tissue disease 10.9
14 collagen disease 10.9
15 gastric leiomyosarcoma 10.8 ENO2 SDHD
16 intracranial primitive neuroectodermal tumor 10.7 CHGA ENO2
17 rete testis adenocarcinoma 10.7 ENO2 NKX2-1
18 epithelioid malignant peripheral nerve sheath tumor 10.7 CHGA ENO2
19 goblet cell carcinoid 10.7 CHGA ENO2
20 acute thyroiditis 10.7 CHGA ENO2
21 rete testis neoplasm 10.7 ENO2 NKX2-1
22 retroperitoneal neuroblastoma 10.6 ENO2 SST
23 duodenal somatostatinoma 10.6 ENO2 SST
24 gastrointestinal neuroendocrine benign tumor 10.6 CHGA SST
25 gastric neuroendocrine neoplasm 10.6 CHGA SST
26 spinal meningioma 10.6 CHGA ENO2
27 spinal canal and spinal cord meningioma 10.6 CHGA ENO2
28 embryoma 10.5 NKX2-1 SYP
29 malignant sertoli cell tumor 10.5 ENO2 SYP
30 diffuse pulmonary fibrosis 10.5 CHGA ENO2
31 sinonasal undifferentiated carcinoma 10.5 ENO2 SYP
32 sensory organ benign neoplasm 10.5 ENO2 SYP
33 cutaneous ganglioneuroma 10.5 ENO2 SYP
34 extrahepatic bile duct adenocarcinoma 10.5 ENO2 SYP
35 papillary tumor of the pineal region 10.5 ENO2 SYP
36 hyperinsulinemic hypoglycemia, familial, 2 10.5 CHGA SST
37 orbital cancer 10.5 ENO2 SYP
38 middle ear adenoma 10.5 ENO2 SYP
39 ovarian carcinosarcoma 10.5 ENO2 SYP
40 esophageal neuroendocrine tumor 10.5 CHGA SYP
41 central nervous system primitive neuroectodermal neoplasm 10.5 ENO2 SYP
42 cerebellum cancer 10.5 ENO2 SYP
43 ovarian large-cell neuroendocrine carcinoma 10.5 CHGA SYP
44 subependymal glioma 10.5 ENO2 SYP
45 cerebral neuroblastoma 10.5 ENO2 SYP
46 acinar cell cystadenocarcinoma 10.5 CHGA SYP
47 peritoneal serous adenocarcinoma 10.5 CHGA SYP
48 cellular ependymoma 10.5 CHGA SYP
49 extraosseous chondrosarcoma 10.5 ENO2 SYP
50 primary hepatic neuroendocrine carcinoma 10.5 CHGA SYP

Graphical network of the top 20 diseases related to Carcinoid Tumors, Intestinal:



Diseases related to Carcinoid Tumors, Intestinal

Symptoms & Phenotypes for Carcinoid Tumors, Intestinal

Symptoms via clinical synopsis from OMIM:

57
Oncology:
intestinal carcinoid
appendiceal carcinoid
malignant carcinoid of ileum


Clinical features from OMIM:

114900

Human phenotypes related to Carcinoid Tumors, Intestinal:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intestinal carcinoid 59 32 Frequent (79-30%) HP:0006723
2 carcinoid tumor 59 Obligate (100%)
3 episodic abdominal pain 59 Frequent (79-30%)
4 protracted diarrhea 59 Frequent (79-30%)
5 small intestine carcinoid 59 Frequent (79-30%)
6 erythematous plaque 59 Frequent (79-30%)
7 night sweats 59 Frequent (79-30%)
8 right ventricular failure 59 Occasional (29-5%)
9 palpitations 59 Occasional (29-5%)
10 nausea and vomiting 59 Occasional (29-5%)
11 asthma 59 Occasional (29-5%)
12 chronic noninfectious lymphadenopathy 59 Occasional (29-5%)
13 elevated hepatic transaminases 59 Occasional (29-5%)
14 increased serum serotonin 59 Occasional (29-5%)
15 tricuspid regurgitation 59 Occasional (29-5%)
16 facial telangiectasia 59 Occasional (29-5%)
17 increased lacrimation 59 Occasional (29-5%)
18 bronchospasm 59 Occasional (29-5%)
19 heart murmur 59 Occasional (29-5%)
20 pulmonary carcinoid tumor 59 Occasional (29-5%)
21 abnormal b-type natriuretic peptide level 59 Occasional (29-5%)
22 rhinorrhea 59 Occasional (29-5%)
23 hepatic necrosis 59 Very rare (<4-1%)
24 paraganglioma 59 Very rare (<4-1%)
25 myopathy 59 Very rare (<4-1%)
26 lack of bowel sounds 59 Very rare (<4-1%)
27 atypical pulmonary carcinoid tumor 59 Very rare (<4-1%)

MGI Mouse Phenotypes related to Carcinoid Tumors, Intestinal:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.65 MEN1 NKX2-1 NOTCH1 SST SSTR2
2 endocrine/exocrine gland MP:0005379 9.63 MEN1 NKX2-1 NOTCH1 SDHD CHGA CHGB
3 homeostasis/metabolism MP:0005376 9.56 MEN1 NKX2-1 NOTCH1 SDHD SST SSTR2
4 nervous system MP:0003631 9.28 ENO2 MEN1 NKX2-1 NOTCH1 SDHD SST

Drugs & Therapeutics for Carcinoid Tumors, Intestinal

Drugs for Carcinoid Tumors, Intestinal (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
5
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
6
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
11
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
14 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
15 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
16 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
17 Antimetabolites Phase 2, Phase 3,Phase 1
18 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
19 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
20 HIV Protease Inhibitors Phase 3,Phase 2
21
protease inhibitors Phase 3,Phase 2
22 Adjuvants, Anesthesia Phase 3
23 Analgesics Phase 3
24 Analgesics, Opioid Phase 3
25 Anesthetics Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3
29 Narcotics Phase 3
30 Peripheral Nervous System Agents Phase 3
31 Anti-Anxiety Agents Phase 3
32 Antiemetics Phase 3
33 Anti-Inflammatory Agents Phase 3
34 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
35 Antipruritics Phase 3
36 Antipsychotic Agents Phase 3
37 Autonomic Agents Phase 3
38 BB 1101 Phase 3
39 Dermatologic Agents Phase 3,Not Applicable
40 Dexamethasone acetate Phase 3 1177-87-3
41 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
42 glucocorticoids Phase 3
43 Hormone Antagonists Phase 3,Phase 2,Phase 1
44 Hormones Phase 3,Phase 2,Phase 1
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
46 Neurotransmitter Agents Phase 3,Phase 2
47 Psychotropic Drugs Phase 3
48 Serotonin Agents Phase 3,Phase 2
49 Serotonin Antagonists Phase 3,Phase 2
50 Tranquilizing Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
5 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
6 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
7 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
8 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
9 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
10 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
11 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
12 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
13 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
14 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
15 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
16 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
17 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
18 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
19 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
20 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
21 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
22 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
23 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
24 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
25 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
26 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
27 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
28 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
29 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
30 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
31 Irinotecan and Capecitabine in Treating Patients With Solid Tumors Unknown status NCT00003867 Phase 1 capecitabine;irinotecan hydrochloride
32 Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions Unknown status NCT00066404 Phase 1
33 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
34 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium
35 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
36 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
37 Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer Completed NCT00003427 Phase 1 irinotecan hydrochloride;oxaliplatin
38 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
39 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
40 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1 cetuximab;erlotinib hydrochloride
41 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
42 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
43 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
44 Interleukin-12 in Treating Patients With Cancer in the Abdomen Completed NCT00003046 Phase 1
45 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
46 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1 entinostat
47 Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer Completed NCT00003439 Phase 1
48 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
49 Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
50 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1

Search NIH Clinical Center for Carcinoid Tumors, Intestinal

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoid tumor

Genetic Tests for Carcinoid Tumors, Intestinal

Anatomical Context for Carcinoid Tumors, Intestinal

MalaCards organs/tissues related to Carcinoid Tumors, Intestinal:

41
Small Intestine, Liver, Breast, Lung, Endothelial, Brain, Pancreas

Publications for Carcinoid Tumors, Intestinal

Articles related to Carcinoid Tumors, Intestinal:

(show all 14)
# Title Authors Year
1
Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. ( 19065104 )
2009
2
AKT and PTEN expression in human gastrointestinal carcinoid tumors. ( 19956439 )
2009
3
Gastrointestinal carcinoid tumor and chylous ascites, a rare association with a poor prognosis. A case report. ( 18705413 )
2008
4
Nuclear translocation of beta-catenin protein but absence of beta-catenin and APC mutation in gastrointestinal carcinoid tumor. ( 17009161 )
2006
5
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. ( 15870121 )
2005
6
Current management of gastrointestinal carcinoid tumors. ( 15358337 )
2004
7
Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. ( 15657590 )
2004
8
Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors. ( 14681318 )
2003
9
Carcinoid syndrome from gastrointestinal carcinoid tumor without distant metastases. ( 12080244 )
2002
10
Different beta-catenin immunoexpression in carcinoid tumors of the appendix in comparison to other gastrointestinal carcinoid tumors. ( 12389996 )
2002
11
Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor. ( 11559529 )
2001
12
Gastrointestinal carcinoid tumors and second primary malignancies. ( 11135275 )
2000
13
[Gastrointestinal carcinoid tumor--an immunohistochemical and histochemical study]. ( 1723678 )
1991
14
Ampullary somatostatinoma: psammomatous variant of gastrointestinal carcinoid tumor--an immunohistochemical and ultrastructural study. Report of a case and review of the literature. ( 6314801 )
1983

Variations for Carcinoid Tumors, Intestinal

Expression for Carcinoid Tumors, Intestinal

Search GEO for disease gene expression data for Carcinoid Tumors, Intestinal.

Pathways for Carcinoid Tumors, Intestinal

Pathways related to Carcinoid Tumors, Intestinal according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 ENO2 NKX2-1 NOTCH1 SYP

GO Terms for Carcinoid Tumors, Intestinal

Biological processes related to Carcinoid Tumors, Intestinal according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 brain development GO:0007420 9.58 MEN1 NKX2-1 NOTCH1
2 negative regulation of osteoblast differentiation GO:0045668 9.43 MEN1 NOTCH1
3 oligodendrocyte differentiation GO:0048709 9.37 NKX2-1 NOTCH1
4 endoderm development GO:0007492 9.32 NKX2-1 NOTCH1
5 neuron fate commitment GO:0048663 9.26 NKX2-1 NOTCH1
6 negative regulation of cell proliferation GO:0008285 9.26 MEN1 NOTCH1 SST SSTR2
7 negative regulation of cell-substrate adhesion GO:0010812 9.16 MEN1 NOTCH1
8 forebrain development GO:0030900 8.8 NKX2-1 NOTCH1 SSTR2

Sources for Carcinoid Tumors, Intestinal

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....